New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For OMX;TSLA;CROX;ANF;SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
March 2, 2015
16:02 EDTTSLAOptions Update; March 2, 2015
iPath S&P 500 VIX Short-Term Futures down 91c to 26.70. Option volume leaders: AAPL TSLA TWTR MBI MCD NFLX AMZN GOOG BAC C according to Track Data.
13:32 EDTTSLATesla starts selling All-Wheel Drive Model S cars in Europe
Subscribe for More Information
12:39 EDTANFAbercrombie & Fitch volatility increases into Q4 and outlook
Abercrombie & Fitch March weekly call option implied volatility is at 161, March is at 83, April is at 62; compared to its 26-week average of 44 according to Track Data, suggesting large March price movement into the expected release of Q4 results on March 4.
12:30 EDTTSLATesla Motors March weekly volatility elevated as shares trade below $200
Tesla Motors March weekly call option implied volatility is at 49, March is at 42, April is at 37, June is at 42; compared to its 26-week average of 45 according to Track Data, suggesting non-directional price movement.
10:06 EDTCROXOptions with decreasing implied volatility
Subscribe for More Information
09:34 EDTTSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL MNTA CELG TSLA MCD ARUN GILD KO TWTR NFLX
06:20 EDTANFAbercrombie & Fitch implied volatility of 64 at upper end of index mean range
February 27, 2015
16:06 EDTTSLAOptions Update; February 27, 2015
Subscribe for More Information
13:10 EDTANFAbercrombie & Fitch March volatility elevated into Q4 and outlook
Subscribe for More Information
11:20 EDTTSLAStocks with call strike movement; TSLA DAL
Tesla (TSLA) June 245 call option implied volatility increased 3% to 40, Delta Air Lines (DAL) June 52.5 call option implied volatility increased 3% to 39 according to IVolatility.
10:12 EDTANFGap rises after Q4 earnings top forecast, capital return plans announced
Subscribe for More Information
09:35 EDTTSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL MCD GOOG MNST BAC TSLA NFLX SINA AMZN WYNN
05:56 EDTANFAbercrombie & Fitch implied volatility of 66 at upper end of index mean range
February 26, 2015
18:43 EDTCROXOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTCROXCrocs sees Q1 reveneue $260M-$265M, consensus $292.2M
Subscribe for More Information
16:07 EDTCROXCrocs reports Q4 revenue $206.5M, consensus $203.24M
Subscribe for More Information
16:00 EDTTSLAOptions Update; February 26, 2015
iPath S&P 500 VIX Short-Term Futures down 33c to 27.78. Option volume leaders: AAPL TSLA TWTR C ZNGA MCD RIG NFLX according to Track Data.
10:29 EDTTSLATesla spikes higher, pivots, levels to watch
Subscribe for More Information
10:22 EDTTSLATesla jumps 2% as Chinese language report fuels speculation
Subscribe for More Information
10:00 EDTANFOn The Fly: Analyst Downgrade SummaryStarz
Subscribe for More Information
09:35 EDTTSLAActive equity options trading on open
Subscribe for More Information
09:05 EDTSPPIFDA grants Sandoz tentative approval of Fusilev generic
The FDA posted on its website that it granted Novartis's Sandoz tentative approval for levoleucovorin calcium, a generic of Spectrum's (SPPI) colon cancer drug Fusilev. Reference Link
08:08 EDTANFAbercrombie & Fitch downgraded at Morgan Stanley
As previously reported, Morgan Stanley downgraded Abercrombie & Fitch to Underweight from Equal Weight. The analyst is skeptical Abercrombie's international business can turn around, and when combined with FX headwinds, will result in FY15 guidance significantly below consensus of $1.69. Morgan Stanley continues to believe teen retailers are in a structural decline and cut Abercrombie's FY15 EPS estimate to $1.30 and lowered its price target to $18 from $28.
07:41 EDTCROXCrocs volatility elevated into Q4 and outlook
Subscribe for More Information
07:34 EDTANFAbercrombie downgraded to Underweight from Equal Weight at Morgan Stanley
06:49 EDTANFAbercrombie & Fitch engaged in Supreme Court trial over Muslim scarf, WSJ says
Subscribe for More Information
06:11 EDTANFStocks with implied volatility above IV index mean; ANF HLF
Stocks with implied volatility above IV index mean; Abercrombie & Fitch (ANF) 64, Herbalife (HLF) 94 according to iVolatility.
February 25, 2015
16:00 EDTTSLAOptions Update; February 25, 2015
Subscribe for More Information
10:10 EDTANFBofA/Merrill retail analysts hold an analyst/industry conference call
Head of European General Retail Equity Research Steegers, along with Head of U.S. General Retail Equity Research Hutchinson, discuss the global apparel sector, focusing on international expansion, pricing and sustainability of margins and returns on an Analyst/Industry conference call to be held on February 25 at 10 am.
09:36 EDTTSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL HPQ PBR FSLR MRVL TSLA LVS ABX TWTR MGM
08:53 EDTANFAbercrombie & Fitch Q4 results could be at low end of view, says Janney Capital
Subscribe for More Information
05:53 EDTANFStocks with implied volatility above IV index mean; ANF HLF
Subscribe for More Information
February 24, 2015
13:13 EDTTSLATesla Model S named 'best overall' by Consumer Reports
Subscribe for More Information
09:35 EDTTSLAActive equity options trading on open
Subscribe for More Information
07:31 EDTSPPIRBC Capital to hold a conference
Subscribe for More Information
06:54 EDTOMXOffice Depot expects to achieve synergy benefits of more than $750M by 2016-end
Subscribe for More Information
05:44 EDTANFStocks with implied volatility above IV index mean; ANF HLF
Subscribe for More Information
February 23, 2015
16:27 EDTSPPIOn The Fly: Closing Wrap
Stocks on Wall Street began the session in negative territory and remained there for most of the session, with the Nasdaq the lone index to post a small gain. The Dow was weighed down by shares of Boeing (BA), which slid after the stock received a downgrade. There was little in the way of positive economic news, as the most notable report showed existing homes were lower than expected due to a shortage of inventory. The averages drifted for most of the session, as investors may be waiting on the sidelines ahead of tomorrow’s banking panel testimony by Fed Chair Janet Yellen. ECONOMIC EVENTS: In the U.S., the Chicago Fed national activity index rebounded to 0.13 in January, which was nearly in-line with expectations. Existing home sales dropped 4.9% to a 4.82M rate in January, which was much worse than the expected 1.8% drop to a 4.95M unit rate. In Europe, the Ifo Institute’s measure of German business confidence rose to 106.8 in February, which was up a tenth of a percentage point from the previous month but below the 107.7 consensus forecast. Also, the Bank of Israel became the latest central bank to cut rates this year, lowering its main interest rate to 0.1% from 0.25%. COMPANY NEWS: The shares of a number of health insurers rose after the Centers for Medicare and Medicaid Services, or CMS, issued preliminary 2016 Medicare Advantage rates. According to Credit Suisse, the rates were favorable for the insurers. Following the CMS announcement made late Friday, Humana (HUM) climbed $8.40, or 5.38%, to $164.52, UnitedHealth (UNH) rose $3.78, or 3.36%, to $116.40, and WellCare (WCG) gained $4.68, or 5.53%, to $89.30. MAJOR MOVERS: Among the notable gainers was PTC Therapeutics (PTCT), which jumped $9.77, or 17.7%, to $64.96 after Reuters said the company is working with financial advisers to explore a potential sale after receiving takeover interest from several companies including Shire (SHPG) and BioMarin (BMRN). Also higher was Valeant (VRX), which rose $25.49, or 14.71%, to $198.75 after the company agreed to buy Salix (SLXP) for $158 per share and also reported better-than-forecast earnings. Salix shares, however, fell $2.09, or 1.32%, to $155.76, as a report Friday from CNBC's David Faber telegraphed the deal and suggested Valeant could value Salix around $160 per share. Among the noteworthy losers was Spectrum Pharmaceuticals (SPPI), which dropped $1.18, or 15.82%, to $6.28 after a judge ruled that a drug which could compete with the company's Fusilev treatment does not infringe on the company's intellectual property. Also lower were shares of Boeing, which fell $3.57, or 2.26%, to $154.74 after the stock was downgraded to Sell from Neutral at Goldman Sachs. INDEXES: The Dow fell 23.60, or 0.13%, to 18,116.84, the Nasdaq gained 5.01, or 0.1%, to 4,960.97, and the S&P 500 slipped 0.64, or 0.03%, to 2,109.66.
16:00 EDTTSLAOptions Update; February 23, 2015
Subscribe for More Information
15:02 EDTTSLATesla Motors February weekly volatility flat on wide intra-day movement
Subscribe for More Information
13:40 EDTSPPIAnalysts clash on Spectrum outlook after patent suit setback
Two research firms had divergent views on Spectrum Pharmaceuticals (SPPI) after a judge ruled that a drug which could compete with the company's Fusilev treatment does not infringe on the company's intellectual property. BACKGROUND: Late Friday, a federal judge ruled that Novartis' (NVS) levoleucovorin, a generic version of Spectrum's Fusilev, does not infringe on Spectrum's intellectual property. Fusilev is indicated after high-dose methotrexate therapy in osteosarcoma, a type of cancer that starts in the bones. It is also used to treat patients with advanced metastatic colorectal cancer. BEARISH TAKE: Roth Capital analyst Joseph Pantginis downgraded Spectrum to Neutral from Buy following the ruling, as he believes the risk to the company's revenue has risen. The company is meaningfully less likely to become profitable again, wrote Pantginis, noting that Fusilev accounted for about 50% of the company's product revenue. According to the analyst, Spectrum is becoming increasingly focused on developing its earlier stage drugs, and he expects those drugs to grow slowly. Pantginis slashed his price target on the shares to $7 from $15. BULLISH TAKE: In a note to investors earlier today, Reni Benjamin, an analyst at research firm H.C. Wainwright, wrote that the stock's plunge after the judge's ruling "creates a table-pounding buying opportunity," noting that Fusilev has been granted exclusivity as a colorectal treatment until 2018. Benjamin does not expect the company's revenue from Fusilev to decline at all until 2018, as a citizen's petition submitted by Spectrum to the FDA, along with an appeal the company is mounting to Friday's ruling, and the difficulty that Novartis will have launching its version of the drug while the appeal is ongoing, will help prevent Spectrum's revenue from dropping. Also likely to protect Spectrum's revenue are the strong relationships that the company has developed with hospitals and community doctors, the analyst stated. He kept a $15 price target and Buy rating on the shares. PRICE ACTION: In mid-afternoon trading, Spectrum tumbled $1.44, or 19.3% to $6.02.
12:21 EDTSPPIOn The Fly: Midday Wrap
Subscribe for More Information
11:32 EDTCROXCrocs reorganizes regional business structure
Subscribe for More Information
10:55 EDTTSLAStocks with call strike movement; TSLA DAL
Subscribe for More Information
10:08 EDTSPPIHigh option volume stocks
Subscribe for More Information
09:59 EDTSPPIOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Antofagasta (ANFGY) downgraded to Sell from Neutral at Goldman... Arch Coal (ACI) downgraded to Sell from Buy at Argus... BHP Billiton (BHP) downgraded to Equal Weight from Overweight at Morgan Stanley... Beazer Homes (BZH) downgraded to Neutral from Buy at Compass Point... Boeing (BA) downgraded to Sell from Neutral at Goldman... Century Communities (CCS) downgraded to Neutral from Overweight at JPMorgan... CyberArk (CYBR) downgraded to Underweight from Neutral at JPMorgan... DirecTV (DTV) downgraded to Hold from Buy at Brean Capital... Enerplus (ERF) downgraded to Hold from Buy at Desjardins... Fiserv (FISV) downgraded to Neutral from Buy at Monness Crespi... GP Strategies (GPX) downgraded to Neutral from Buy at B. Riley... Interactive Brokers (IBKR) downgraded to Market Perform at Keefe Bruyette... MRC Global (MRC) downgraded at BB&T... Precision Castparts (PCP) downgraded to Neutral from Buy at Goldman... Quest Diagnostics (DGX) downgraded at BofA/Merrill... Rio Tinto (RIO) downgraded to Equal Weight from Overweight at Morgan Stanley... Roth Capital downgraded Spectrum (SPPI) on court case loss... Royal Dutch Shell (RDS.A) downgraded to Sector Perform from Outperform at Howard Weil... Ryland Group (RYL) downgraded to Neutral from Buy at Compass Point... Salix (SLXP) downgraded to Market Perform from Outperform at Leerink... Standard Pacific (SPF) downgraded to Neutral from Buy at Compass Point... Superior Energy (SPN) downgraded to Neutral from Outperform at Credit Suisse... Transocean (RIG) downgraded to Negative from Neutral at Susquehanna... Vale (VALE) downgraded to Equal Weight from Overweight at Morgan Stanley.
09:39 EDTTSLAActive equity options trading on open
Subscribe for More Information
09:25 EDTSPPIOn The Fly: Pre-market Movers
Subscribe for More Information
08:56 EDTTSLATesla long-term focus likely to 'lose luster' with investors, says BofA/Merrill
Subscribe for More Information
08:44 EDTSPPIRoth Capital downgraded Spectrum on court case loss
Subscribe for More Information
07:16 EDTSPPISpectrum pullback a 'table-pounding' buying opportunity, says H.C. Wainwright
H.C. Wainwright calls the sell-off in shares of Spectrum Pharmaceuticals (SPPI) after a District Court in Nevada ruled that the levoleucovorin formulation used by Sandoz does not infringe the company's Fusilev intellectual property as a "table-pounding" buying opportunity. The firm reminds investors that Fusilev is still protected by orphan drug exclusivity until 2018 as a treatment for patients with colorectal cancer. It keeps a Buy rating on Spectrum with a $15 price target.
07:14 EDTSPPISpectrum says plans to appeal patent suit loss to Novartis unit
Spectrum Pharmaceuticals (SPPI) confirmed in a regulatory filing that on February 20, the U.S. District Court for the District of Nevada ordered that judgment be entered in favor of defendant Sandoz in the matter entitled Spectrum Pharmaceuticals, Inc. et al v. Sandoz Inc. "Spectrum Pharmaceuticals Inc. intends to appeal this decision and the ultimate outcome of this litigation remains uncertain," the company stated. Sandoz is the generic pharmaceuticals division of Novartis (NVS).
06:40 EDTCROXCrocs price target lowered to $10 from $13 at Piper Jaffray
Subscribe for More Information
06:09 EDTANFStocks with implied volatility above IV index mean; ANF HLF
Subscribe for More Information
06:08 EDTSPPISpectrum downgraded to Neutral from Buy at Roth Capital
February 20, 2015
17:48 EDTSPPISpectrum awards 2014 cash performance awards to C-level executives
On February 18, the compensation committee of the board of Spectrum Pharmaceuticals determined that the company materially accomplished substantially all major goals established at the outset of 2014. Based on an assessment of the company’s performance, the committee determined cash performance awards for its CEO, Rajesh Shrotriya, who got a salary increase of 5.0% and a $900,000 cash bonus; its COO, Joseph Turgeon, who got a 4.5% raise and a $330,000 bonus; its CFO, Kurt A. Gustafson, who got a 4.4% raise and a $225,000 bonus; and its Chief Medical Officer, Lee F. Allen, who got a 3.4% raise and a $270,000 bonus. The Fly notes that Spectrum's stock is down 30% in after-hours trading after a Bloomberg report that the company had its Fusilev patent ruled invalid by a Nevada court.
16:37 EDTSPPISpectrum down 34% after Fusilev patent reportedly ruled invalid
Subscribe for More Information
16:36 EDTSPPISpectrum Fusilev patent ruled invalid by court, Bloomberg reports
16:03 EDTTSLAOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTTSLAActive equity options trading on open
Subscribe for More Information
09:23 EDTANF, CROXGoldman sees select Apparel and Footwear opportunities due to FX risk
Goldman said translation currency exposure in the Apparel and Footwear has created volatility and opportunity to gain exposure to this theme. Goldman's analyst sees a positive near-term set-up for Nike (NKE) and Tiffany (TIF) and a negative set-up for Crocs (CROX) and Abercrombie & Fitch (ANF) and of upcoming earnings reports.
06:41 EDTTSLAApple pushing for 2020 production of its electric car, Bloomberg says
Apple (AAPL) is pushing to begin production of its electric vehicle as soon as 2020, reports Bloomberg, citing people with knowledge of the matter. Bloomberg notes that the move could put Apple into direct competition with Tesla (TSLA) and General Motors (GM), both of which are targeting a 2017 release for next-generation electric vehicles. Apple may still cancel the project if it becomes unhappy with progress, the sources said, though its vehicle team is already 200-people strong. Reference Link
06:00 EDTANFAbercrombie & Fitch March volatility elevated into Q4 and spring outlook
Subscribe for More Information
04:19 EDTANFStocks with implied volatility movement; AMAT ANF
Subscribe for More Information
February 19, 2015
09:44 EDTTSLATesla shares can hit new highs by year end, says Morgan Stanley
Subscribe for More Information
09:35 EDTTSLAOption volume leaders
Option volume leaders: AAPL TSLA TWTR MCD WMT PBR SPWR WFM GILD FB SCTY according to Track Data.
06:13 EDTCROXCrocs volatility elevated into Q4 and outlook
Subscribe for More Information
05:31 EDTANFStocks with implied volatility above IV index mean; HLF ANF
Subscribe for More Information
February 18, 2015
16:00 EDTTSLAOptions Update; February 18, 2015
Subscribe for More Information
12:00 EDTTSLATesla executive says U.S. demand surged due to P85D, Bidness reports
Mateo Jaramillo, Tesla Director of Powertrain Business Development, said that Model S wait times in the U.S. have grown to about a month and half to two months due to a "genuine surge" in orders for the upgraded and faster P85D model, reported Bidness Etc. Reference Link
09:37 EDTTSLAOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
February 17, 2015
16:00 EDTTSLAOptions Update; February 17, 2015
Subscribe for More Information
10:31 EDTTSLAApple rises as analysts applaud reported auto ambitions
Subscribe for More Information
09:40 EDTTSLAActive equity options trading on open
Subscribe for More Information
05:42 EDTANFAbercrombie & Fitch implied volatility of 58 at upper end of index mean range
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use